[1] Ramai D, Ofosu A, Lai JK, et al. Fibrolamellar hepatocellular carcinoma: a population-based observational study. Dig Dis Sci,2021,66(1):308-314.
[2] Mavros MN, Mayo SC, Hyder O,et al. A systematic review: treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma. J Am Coll Surg, 2012,215(6):820-830.
[3] Darcy DG, Malek MM, Kobos R, et al. Prognostic factors in fibrolamellar hepatocellular carcinoma in young adults. J Pediatr Surg,2015,50(1):153-156.
[4] Yamashita S, Vauthey JN, Kaseb AO, et al. Prognosis of fibrolamellar carcinoma compared to non-cirrhotic conventional hepatocellular carcinoma. J Gastrointest Surg,2016,20(10):1725-1731.
[5] Groeschl RT, Miura JT, Wong RK, et al. Multi-institutional analysis of recurrence and survival after hepatectomy for fibrolamellar carcinoma. J Surg Oncol, 2014,110(4):412-415.
[6] Eng JY, Soon SY, Winnie Ling HY. Curative lung metastectomy and complete pathological response after neo-adjuvant GEMOX chemotherapy for relapse fibrolamellar hepatocellular carcinoma.Med J Malaysia,2018,73(1):46-48. |
